Results 151 to 160 of about 661,753 (260)

Erratum: [Corrigendum] Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer. [PDF]

Oncol Lett
Maehana T, Kawaguchi R, Nishikawa K, Kawahara N, Yamada Y, Kimura F.   +5 more
europepmc   +1 more source

Genetic variation of the blood coagulation regulator tissue factor pathway inhibitor and venous thromboembolism among middle-aged and older adults: A population-based cohort study. [PDF]

Res Pract Thromb Haemost, 2022
Manderstedt E, Lind-Halldén C, Halldén C, Elf J, Svensson PJ, Engström G, Melander O, Baras A, Lotta LA, Zöller B, Regeneron Genetics Center.   +10 more
europepmc   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

The diagnostic efficiency of tissue factor pathway inhibitor 2 methylation in the detection of colorectal cancer: a systematic review and meta-analysis. [PDF]

J Gastrointest Oncol
Wang XL, Qin S, Liu L, Jia YQ, Wang Y, Zhou YJ, Ramos-Molina B, Valladares-Ayerbes M, Eidens M, Liu ZZ.   +9 more
europepmc   +1 more source

Circulating Syndecan-1 and Tissue Factor Pathway Inhibitor, Biomarkers of Endothelial Dysfunction, Predict Mortality in Burn Patients. [PDF]

Shock, 2021
Keyloun JW, Le TD, Pusateri AE, Ball RL, Carney BC, Orfeo T, Brummel-Ziedins KE, Bravo MC, McLawhorn MM, Moffatt LT, Shupp JW, and the SYSCOT study group.   +11 more
europepmc   +1 more source

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

FEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová, Grigorii Rakhalskii, Miroslav Almáši   +2 more
wiley   +1 more source

Tissue factor pathway inhibitor levels and atherothrombotic events in patients with chronic kidney disease or diabetes. [PDF]

J Thromb Thrombolysis
Brook R, Suleiman M, Rigano J, Lui B, Nandurkar H, Ho P, Lim HY.   +6 more
europepmc   +1 more source

Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency. [PDF]

Blood Adv, 2021
Mehic D, Tolios A, Hofer S, Ay C, Haslacher H, Rejtö J, Ouwehand WH, Downes K, Haimel M, Pabinger I, Gebhart J.   +10 more
europepmc   +1 more source

Aquaporin‐3 and aquaporin‐5 impact the development of pancreatic ductal adenocarcinoma spheroids

FEBS Open Bio, EarlyView.
Schematic representation of the role of aquaporin‐3 (AQP3) and aquaporin‐5 (AQP5) in pancreatic ductal adenocarcinoma (PDAC). Both proteins are upregulated in PDAC and are associated with tumor progression and metastatic potential. Silencing AQP3 or AQP5 in PDAC spheroids results in decreased diameter, area, and overall growth, underscoring their key ...
Catarina Pimpão, Diogo M. Engrácia, Graça Soveral, Filipa Mendes   +3 more
wiley   +1 more source

Elevated tissue factor pathway inhibitor delays thrombin generation in COVID-19 but is not associated with clinical outcomes. [PDF]

Blood Vessel Thromb Hemost
Eustes AS, Palani Kumar MK, Peterson JA, Mast AE, Lentz SR, Dayal S.   +5 more
europepmc   +1 more source